Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. (September 2014)

• Record Type: Journal Article
• Authors: Diener, Hans-Christoph; Stanford, Sophia; Abdul-Rahim, Azmil; Christensen, Louisa; Hougaard, Kristina Dupont; Bakhai, Ameet; Veltkamp, Roland; Worthmann, Hans
• Is Part Of: Expert review of neurotherapeutics. Volume 14:Number 9(2014)
• Page Start: 1019
• Page End: 1028
• Publication Date: 2014-09
• Subjects: Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1586/14737175.2014.945435
• Languages: English
• ISSNs: 1473-7175

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Patients with atrial fibrillation have an increased risk of ischemic stroke that can be dramatically lowered by treatment with anticoagulants. The annual rate of major bleeds with warfarin averages about 2%. The rates of intracerebral and intracranial bleeds are significantly reduced with the use of the novel direct oral anticoagulants (DOACs) compared with warfarin. Treatment of anticoagulation-related intracerebral hemorrhage is based on the results of case series and small trials. Resumption of anticoagulation in patients with atrial fibrillation who had an intracerebral bleed depends on the etiology and location of the bleeding and the absolute rate of stroke in the absence of anticoagulation.</p> </abstract>